AI Investing Insights - Official Homepage

News

G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies

4.5

01-20aastocks

Midday Update: HSI Ends at 26,552, Down 11 Points; HSTI at 5,711, Down 38 Points; POP MART Rises Over 8%; LUK FOOK HOLD, NANSHAN AL INTL, CHINA EAST AIR, CTG DUTY-FREE, and CHINA TAIPING Reach New Highs

4.5

01-20aastocks

M Stanley Identifies Top Thematic Investment Opportunities in APAC, Featuring Japanese Stocks (Table)

4.5

01-19aastocks

HSI Declines 265 Points at Midday as Certain AI and Pharma Stocks Drop; Power Equipment Stocks Rise

4.0

01-14aastocks

Citi Places WUXI APPTEC on 90-Day Upside Catalyst Watch with Target Price of HKD142

Money Flow

Over the past 66 trading days, overall net money flow is 95.98M, with retail investors contributing 12.28M and major investors adding 45.09M.

Net Buy $ Volume

Net Sell $ Volume

CLSA

Outperform

maintain

$143.4

2026-01-07

Reason

The analyst rating of Outperform for WUXI APPTEC (02359.HK) by CLSA is based on several key factors. The broker anticipates that WUXI APPTEC will benefit from a rebound in outsourcing demand and reduced policy uncertainty, leading to significant earnings growth in 2026. Additionally, three major catalysts in the first quarter of 2026 are expected to drive the company's share price performance: 1. An industry summit from January 12-15 that will provide updates on the CRO industry and boost market confidence. 2. The announcement of the US Department of Defense's 1260H list between January and February, which is expected to alleviate concerns about policy uncertainties. 3. The company's 2026 results guidance in March, which will further confirm its earnings growth potential. These factors contribute to the positive outlook and the raised target price of $143.4.

CLSA

Outperform

Price Target

$143.4

2026-01-07

maintain

The analyst rating of Outperform for WUXI APPTEC (02359.HK) by CLSA is based on several key factors. The broker anticipates that WUXI APPTEC will benefit from a rebound in outsourcing demand and reduced policy uncertainty, leading to significant earnings growth in 2026. Additionally, three major catalysts in the first quarter of 2026 are expected to drive the company's share price performance: 1. An industry summit from January 12-15 that will provide updates on the CRO industry and boost market confidence. 2. The announcement of the US Department of Defense's 1260H list between January and February, which is expected to alleviate concerns about policy uncertainties. 3. The company's 2026 results guidance in March, which will further confirm its earnings growth potential. These factors contribute to the positive outlook and the raised target price of $143.4.

BOCI

Buy

upgrade

$122 -> $127

2025-10-30

Reason

The analyst rating for WUXI APPTEC was influenced by the company's strong financial performance in its 3Q25 results, which exceeded expectations. BOCI highlighted a year-over-year increase of 15% in revenue and 53% in net profit, driven by the scaling up of late-stage clinical and commercialization projects. Additionally, the company's gross profit margin (GPM) improved significantly, rising by 7.8 percentage points to 49.8%. As a result of this positive performance, BOCI raised its target price for the stock and maintained a Buy rating.

BOCI

Buy

Price Target

$122 -> $127

2025-10-30

upgrade

The analyst rating for WUXI APPTEC was influenced by the company's strong financial performance in its 3Q25 results, which exceeded expectations. BOCI highlighted a year-over-year increase of 15% in revenue and 53% in net profit, driven by the scaling up of late-stage clinical and commercialization projects. Additionally, the company's gross profit margin (GPM) improved significantly, rising by 7.8 percentage points to 49.8%. As a result of this positive performance, BOCI raised its target price for the stock and maintained a Buy rating.

HSBC Global Research

Buy

upgrade

$124

2025-08-27

Reason

HSBC Global Research

Buy

Price Target

$124

2025-08-27

upgrade

CLSA

Outperform

maintain

2025-08-25

Reason

CLSA

Outperform

Price Target

2025-08-25

maintain

Citi

Citi Research

upgrade

$95 -> $130

2025-07-30

Reason

WUXI APPTEC (02359.HK) +0.300 (+0.269%) Short sellingxa0$457.46M;xa0Ratioxa020.855% 's management raised its 2025 guidance, primarily due to rapid output expansion, instead of a surge in orders before the tariff war, Citi Research issued a research report saying. The continuous operating revenue is expected to reach RMB42.5-43.5 billion, up 13-17% YoY (compared to previous guidance of RMB41.5-43 billion, up 10-15% YoY). Related News UBS Rates WUXI APPTEC as Buy w/ TP HKD104.6; Interim Results in Line Based on gross profit margin expansion driven by the chemical business, a decline in administrative expense ratio and higher investment returns, Citi Research raised its 2025-2027 EPS forecasts for WUXI APPTEC by 3%/ 6%/ 7% each. Therefore, given the more optimistic earnings outlook, the broker elevated its target prices for WUXI APPTEC's H-/ A-shares from $95/ RMB88 to $130/ RMB119. WUXI APPTEC is the broker's top pick in the CDMO sector, with rating at Buy. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-30 16:25.)

Citi

Price Target

$95 -> $130

2025-07-30

upgrade

WUXI APPTEC (02359.HK) +0.300 (+0.269%) Short sellingxa0$457.46M;xa0Ratioxa020.855% 's management raised its 2025 guidance, primarily due to rapid output expansion, instead of a surge in orders before the tariff war, Citi Research issued a research report saying. The continuous operating revenue is expected to reach RMB42.5-43.5 billion, up 13-17% YoY (compared to previous guidance of RMB41.5-43 billion, up 10-15% YoY). Related News UBS Rates WUXI APPTEC as Buy w/ TP HKD104.6; Interim Results in Line Based on gross profit margin expansion driven by the chemical business, a decline in administrative expense ratio and higher investment returns, Citi Research raised its 2025-2027 EPS forecasts for WUXI APPTEC by 3%/ 6%/ 7% each. Therefore, given the more optimistic earnings outlook, the broker elevated its target prices for WUXI APPTEC's H-/ A-shares from $95/ RMB88 to $130/ RMB119. WUXI APPTEC is the broker's top pick in the CDMO sector, with rating at Buy. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-30 16:25.)

Valuation Metrics

Forward PE

N/A

5Y Average PE

6.22

Current PE

17.15

Overvalued PE

15.10

Undervalued PE

-2.67

Forward EV/EBITDA

N/A

5Y Average EV/EBITDA

15.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

24.39

Undervalued EV/EBITDA

7.19

Forward PS

N/A

5Y Average PS

6.09

Current PS

0.00

Overvalued PS

8.32

Undervalued PS

3.87

Financials

AI Analysis

Annual

Quarterly

Trading Trends

Daily

Monthly

Buyback

Short Selling

People Also Watch